Form D · Biotechnology
VACCINOGEN INC
Baltimore, MD · CIK 0001453001
Offering snapshot reported Nov 9, 2015 · SEC filing
- Reported sold
- $600K Offering amount: $3M
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 27, 2015 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 9, 2015 | Initial | $600,000 | No comparison | 4 | SEC filing |
| Aug 24, 2015 | Amendment | $0 | No comparison | 7 | SEC filing |
| Aug 20, 2015 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Aug 20, 2015 | Initial | Yet to sell | No comparison | 7 | SEC filing |
| Jan 24, 2014 | Amendment | $6,642,878 | $4,581,313vs Mar 22, 2013 | 68 | SEC filing |
| Mar 22, 2013 | Initial | $2,061,565 | No comparison | 22 | SEC filing |
| Sep 4, 2012 | Initial | $0 | No comparison | 1 | SEC filing |
| Jun 3, 2011 | Amendment | $7,600,000 | $4,850,000vs Mar 11, 2010 | 25 | SEC filing |
| Oct 14, 2010 | Initial | $0 | No comparison | 1 | SEC filing |
| Jul 2, 2010 | Initial | $0 | No comparison | 1 | SEC filing |
| Mar 11, 2010 | Initial | $2,750,000 | No comparison | 4 | SEC filing |
| Feb 19, 2010 | Amendment | $4,008,472 | No comparison | 66 | SEC filing |
| Dec 23, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-250918
Source: Form D, filed Nov 9, 2015. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Gregory H. Barnhill | Director |
| Tony Caplin | Director |
| Alan Cohen | Director |
| Hakan Edstrom | Director |
| Dan Fitzgerald | Director |
| Daniel Fitzgerald | Director |
| Michael Hagerman | Director |
| Anders Halldin | Director |
| Michael G. Hanna, Jr. | Director |
| David Hatt | Director |
| Ronald Kaiser | Director |
| Daniel Kane | Director |
| Michael Kranda | Director, Executive |
| John Nicolis | Director |
| Andrew L. Tussing | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
949 Fell Street
Baltimore, MD, 21231
Baltimore, MD, 21231